• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immuneering Corp Cl A (NQ: IMRX )

    1.280 -0.060 (-4.48%)
    Streaming Delayed Price Updated: 12:14 PM EDT, Jul 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Immuneering Corp Cl A

    < Previous 1 2 3 4 5 Next >
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Immuneering to Present at the Jefferies Global Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
    IMRX stock results show that Immuneering missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Recognizes Melanoma Awareness Month
    From Immuneering Corporation
    Via GlobeNewswire
    IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
    From Immuneering Corporation
    Via GlobeNewswire
    3 Stocks Insiders Are Buying That Analysts Love
    Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits. 
    Via MarketBeat
    March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
    Via AB Newswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates. 
    Via Benzinga
    Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
    Immuneering shares dip as analysts express concern over IMM-1-104 trial results. Needham downgrades, citing efficacy issues despite promising mechanism of action. Optimism remains for earlier-stage... 
    Via Benzinga
    Dow Falls Over 200 Points; Adobe Shares Plunge
    U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&P... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Crude Oil Edges Lower; US Consumer Sentiment Falls In March
    U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded down 0.37% to 38,761.74 while the NASDAQ fell 0.95% to 15,974.83. The S&P 500... 
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    What's Going On With Cancer-Focused Immuneering Stock On Thursday?
    Unlock the latest Phase 1 trial results for IMM-1-104 by Immuneering. Discover how 320mg and 240mg doses inhibit tumor progression and evaluate safety profiles. 
    Via Benzinga
    US Stocks Higher; Producer Prices Rise 0.6% In February
    U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.11% to 39,084.58 while the NASDAQ rose 0.30% to 16,226.13. The S&P... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
    Former Chairman, CEO and Founder of ChemoCentryx, Inc. 
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
    From Immuneering Corporation
    Via GlobeNewswire
    Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
    EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering to Participate in the Cowen 44th Annual Health Care Conference
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
    From Immuneering Corporation
    Via GlobeNewswire
    3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
    Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.